Stock screenerAll disclosures →
EDGAR →
ACAD
Conviction 34HealthcareScan · Thu, Sep 24, 2026Acadia Pharmaceuticals Inc (ACAD) closed at $22.19 (-12.74%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 20, RS Rating 35, -27.4% from its 52-week high, -15.6% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.
ACAD$22.19-12.74%
ResistanceSupportVol 14Insider sell2
Vol MA14 2.19M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price22.19
Change-12.74%
Gap-4.80%
Rel volume5.82×
Avg volume1.92M
Avg $ vol50.5M
SMA 2027.46
SMA 5027.55
SMA 20024.60
Price vs 50-19.46%
Price vs 200-9.78%
MA stackmixed
50/200 cross—
Supertrenddown · 26.52
RSI (14)20
MACD hist-0.53
MACD cross—
Stoch %K / %D3 / 6
ADX (14)24
+DI / −DI13 / 48
RSI divergence—
MACD divergenceBullish
ATR %4.78%
ADR %3.29%
52w high30.57
52w low20.06
From 52w high-27.41%
Above 52w low+10.62%
New 52w highNo
SqueezeOff
Bollinger width22.94%
%B-0.34
Donchian pos2.43%
Donchian high29.83
Donchian low22.00
AVWAP (52w high)27.18
vs AVWAP high-18.37%
AVWAP (52w low)24.20
vs AVWAP low-8.32%
OBV trendDown
Chaikin MF (20)-0.29
Today vs 20d5.82×
Avg vol (14d)2.19M
Avg vol (20d)1.92M
Avg $ vol (20d)50.5M
Market cap3.82B
RS Rating35 / 99
RS 3m (vs SPY)-10.94%
RS 6m (vs SPY)-16.00%
RS line new highNo
Trend template1/8
Technical rank25.2
1 week-19.16%
1 month-27.41%
3 months-6.45%
6 months+0.82%
1 year-5.97%
YTD-15.60%
P/E9.78
P/B2.93
P/S3.57
P/FCF36.36
EPS2.30
Div yield—
ROE29.92%
ROA22.43%
Debt/Eq0.00
Current3.39
EV/EBITDA32.74
Gross margin63.91%
Net margin36.49%
Rev growth11.87%
EPS growth72.66%
Price target34.93
Target upside57.41%
Analyst ratingBuy
Institutional107.07%
Ent. value3.44B
Revenue307.96M
Net income31.5M
Gross profit—
Free cash flow105.15M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out171.24M
Employees798
ListedThu, May 27, 2004
Free float126.37M
Float %74.1%
Short interest9.74M
Days to cover6.9d
Short volume32.4%
Squeeze score55 / 100
Next earnings—
EPS forecast—
Last EPS vs est$0.18 vs $0.06
Last surprise+200.0% beat
Setup gradeD
Conviction34 / 100
Pattern quality—
Tech rank25.2 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance30.86
Support26.87
Days since event—
Candle confirm—
Financials as of Tue, Jun 30, 2026 · quarterly.
Recent news
- Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026Tikr · Thu, Sep 24, 2026
- ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20%Stocktwits · Thu, Sep 24, 2026
- Why Is Acadia Pharmaceuticals Stock Tumbling Today? - ACADIA Pharmaceuticals (NASDAQ:ACAD)Benzinga · Thu, Sep 24, 2026
- Acadia Pharmaceuticals: Remlifanserin Is In Trouble (NASDAQ:ACAD)Seeking Alpha · Thu, Sep 24, 2026
- Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis dataProactiveinvestors · Thu, Sep 24, 2026
- ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer’s Psychosis TrialMarketbeat · Thu, Sep 24, 2026
- Bears Chase Down Acadia Pharma After Surprise Alzheimer's SetbackYahoo Finance · Thu, Sep 24, 2026
- $ACAD stock is down 8% today. Here's what we see in our data.Quiver Quantitative · Thu, Sep 24, 2026
- ACADIA Pharmaceuticals (ACAD) Drops 8.6% to $23.25AlphaStreet · Thu, Sep 24, 2026
- Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary EndpointAdvfn · Thu, Sep 24, 2026
Congress activity
Disclosed STOCK Act trades in ACAD
No recent disclosed trades by Congress in ACAD. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in ACAD · open-market 4 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER · Common Stock · 2026-08-06 | Sell | 9.29K | $273K | 2026-08-06 | 2026-08-07 |
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER · Stock Option (Right to Buy) · 2026-08-06 | Exercise | 14.29K | — | 2026-08-06 | 2026-08-07 |
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER · Common Stock · 2026-08-06 | Exercise | 14.29K | $255K | 2026-08-06 | 2026-08-07 |
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER · Common Stock · 2026-08-06 | Sell | 5K | $145K | 2026-08-06 | 2026-08-07 |
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER · Common Stock · 2026-08-05 | Exercise | 5.85K | $104K | 2026-08-05 | 2026-08-07 |
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER · Stock Option (Right to Buy) · 2026-08-05 | Exercise | 5.85K | — | 2026-08-05 | 2026-08-07 |
Schneyer Mark C. EVP, CHIEF FINANCIAL OFFICER · Common Stock · 2026-08-05 | Sell | 5.85K | $170K | 2026-08-05 | 2026-08-07 |
Kihara James PRINCIPAL ACCOUNTING OFFICER · Common Stock · 2026-06-26 | Sell | 11.42K | $298K | 2026-06-26 | 2026-06-29 |
Baker Bros. Advisors (GP) LLC Director · Common Stock · 2026-05-29 | Grant | 18.62K | $0 | 2026-05-29 | 2026-06-02 |
BAKER FELIX Director · Common Stock · 2026-05-29 | Grant | 18.62K | $0 | 2026-05-29 | 2026-06-02 |
SEC filings
EDGAR filings in ACAD · 6 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.